Nortriptyline for smoking cessation: a review.

This article reviews the efficacy of nortriptyline for smoking cessation based on a meta-analysis of the Cochrane Library. Six placebo-controlled trials have shown nortriptyline (75-100 mg) doubles quit rates (OR = 2.1). Between 4% and 12% of smokers dropped out because of adverse events, but no serious adverse events occurred. The efficacy of nortriptyline did not appear to be related to its antidepressant actions. Nortriptyline is an efficacious aid to smoking cessation with a magnitude of effect similar to that for bupropion and nicotine replacement therapies. Whether nortriptyline produces serious side effects at these doses in healthy, nondepressed smokers remains unclear because it has been tested in only 500 smokers. The finding that nortriptyline and bupropion are effective for smoking cessation but that selective serotonin-reuptake inhibitors are not suggests that dopaminergic or adrenergic, but not serotonergic, activity is important for cessation efficacy. Until further studies can verify a low incidence of significant adverse events, nortriptyline should be a second-line treatment for smoking cessation.

[1]  M. Zeegers,et al.  Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. , 2005, Addiction.

[2]  T. Miyoshi,et al.  [A randomized trial of notriptyline combined with transdermal nicotine for smoking cessation]. , 2004, Revista portuguesa de pneumologia.

[3]  S. Hall,et al.  Extended nortriptyline and psychological treatment for cigarette smoking. , 2004, The American journal of psychiatry.

[4]  F. Gasparini,et al.  Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. , 2003, Drug discovery today.

[5]  M. Jarvis.  Monitoring cigarette smoking prevalence in Britain in a timely fashion. , 2003, Addiction.

[6]  Y. Gerber,et al.  A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. , 2003, Addiction.

[7]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[8]  P. Jatlow,et al.  A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation , 2003, Biological Psychiatry.

[9]  S. Hall,et al.  Psychological intervention and antidepressant treatment in smoking cessation. , 2002, Archives of general psychiatry.

[10]  I. Berlin,et al.  Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. , 2002, Addiction.

[11]  M. Lourenço,et al.  Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. , 2002, Chest.

[12]  D. Wetter,et al.  Predicting relapse back to smoking: contrasting affective and physical models of dependence. , 2002, Journal of consulting and clinical psychology.

[13]  B. Jamerson,et al.  Effect of Nonnicotine Pharmacotherapy on Smoking Behavior , 2001, Pharmacotherapy.

[14]  P. Kenny,et al.  Neurobiology of the nicotine withdrawal syndrome , 2001, Pharmacology Biochemistry and Behavior.

[15]  M. Raw,et al.  WHO Europe evidence based recommendations on the treatment of tobacco dependence , 2001, Tobacco control.

[16]  A. Buist,et al.  Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation , 2001, Annals of Internal Medicine.

[17]  G. Koob,et al.  Drug Addiction, Dysregulation of Reward, and Allostasis , 2001, Neuropsychopharmacology.

[18]  Robert West,et al.  Smoking cessation guidelines for health professionals: an update , 2000, Thorax.

[19]  N. Benowitz,et al.  The use of pharmacotherapies for smoking cessation during pregnancy , 2000, Tobacco control.

[20]  N. Benowitz,et al.  Non-Nicotine Pharmacotherapy for Smoking Cessation , 2000 .

[21]  J. Hughes,et al.  Treatment Resistant Smokers , 2000, Journal of addictive diseases.

[22]  N. Benowitz,et al.  Drug Interactions with Tobacco Smoking , 1999, Clinical pharmacokinetics.

[23]  R. Lukas,et al.  Antidepressants Noncompetitively Inhibit Nicotinic Acetylcholine Receptor Function , 1999, Journal of neurochemistry.

[24]  A. Prochazka,et al.  A randomized trial of nortriptyline for smoking cessation. , 1998, Archives of internal medicine.

[25]  S. Hall,et al.  Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. , 1998, Archives of general psychiatry.

[26]  E. Levin,et al.  Nicotinic acetylcholine involvement in cognitive function in animals , 1998, Psychopharmacology.

[27]  S. Greenland,et al.  A Meta-Analysis to Assess the Incidence of Adverse Effects Associated with the Transdermal Nicotine Patch , 1998, Drug safety.

[28]  M. Fiore,et al.  Listening to Nicotine: Negative Affect and the Smoking Withdrawal Conundrum , 1997 .

[29]  Y. Lecrubier,et al.  A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers , 1995, Clinical pharmacology and therapeutics.

[30]  R. Jeffery,et al.  Weight concerns and smoking: A literature review , 1995, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[31]  S. Dilsaver.  Withdrawal Phenomena Associated with Antidepressant and Antipsychotic Agents , 1994, Drug safety.

[32]  D. Krahn,et al.  Blindness and the validity of the double-blind procedure. , 1985, Journal of clinical psychopharmacology.

[33]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[34]  Cigarette smoking among adults--United States, 2002. , 2004, MMWR. Morbidity and mortality weekly report.

[35]  T. George,et al.  Current pharmacological treatments for nicotine dependence. , 2004, Trends in pharmacological sciences.

[36]  Josue P. Keely,et al.  Measures of abstinence in clinical trials: issues and recommendations. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[37]  K. Warner,et al.  Hardening and the hard-core smoker: concepts, evidence, and implications. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[38]  Richard A. Brown,et al.  Patterns of change in depressive symptoms during smoking cessation: who's at risk for relapse? , 2002, Journal of consulting and clinical psychology.